{"id":"atr04-484","_chembl":null,"_dailymed":null,"_scrapedAt":"2026-03-28T04:56:08.931Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779123655,"model":"claude-sonnet-4-5-20250929"},"description":"ATR04-484 is an investigational therapeutic developed by Azitra Inc., currently in Phase 1 clinical development. Limited public information is available regarding its molecular target, mechanism of action, or specific therapeutic indications at this early stage of development.","indications":{"approved":[{"status":"investigational","condition":null,"patientPopulation":null}]},"trialDetails":[{"nctId":"NCT06830863","phase":"PHASE1, PHASE2","title":"A Study to Evaluate Topical ATR04-484 for EGFRi-Associated Dermal Toxicity","status":"RECRUITING","sponsor":"Azitra Inc.","startDate":"2025-08-25","conditions":"EGFR Inhibitor-associated Rash","enrollment":32}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ATR-04"],"phase":"phase_1","status":"active","brandName":"ATR04-484","genericName":"ATR04-484","companyName":"Azitra Inc.","companyId":"azitra-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":1,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}